State Street
AVBP icon

State Street’s ArriVent BioPharma AVBP Stock Holding History

State Street’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.8M Buy
1,692,986
+271,571
+19% +$8.02M ﹤0.01% 1752
2026
Q1 		$32.8M Buy
1,421,415
+329,435
+30% +$7.44M ﹤0.01% 1964
2025
Q4 		$22M Buy
1,091,980
+64,352
+6% +$1.34M ﹤0.01% 2215
2025
Q3 		$19M Buy
1,027,628
+286,836
+39% +$5.64M ﹤0.01% 2285
2025
Q2 		$16.1M Sell
740,792
-26,948
-4% -$560K ﹤0.01% 2309
2025
Q1 		$14.2M Sell
767,740
-46,351
-6% -$1.13M ﹤0.01% 2314
2024
Q4 		$21.7M Buy
814,091
+337,282
+71% +$9.68M ﹤0.01% 2190
2024
Q3 		$11.2M Buy
476,809
+323,186
+210% +$7.34M ﹤0.01% 2532
2024
Q2 		$2.85M Buy
153,623
+31,359
+26% +$559K ﹤0.01% 3169
2024
Q1 		$2.18M Buy
+122,264
New +$2.47M ﹤0.01% 3254

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street's AVBP Position: Q2 2026 in Review

State Street increased its ArriVent BioPharma (AVBP) stake by 19% in Q2 2026, buying an estimated $8.02M and bringing the position to 1,692,986 shares worth $58.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1752.

State Street first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • State Street held 1,692,986 shares of ArriVent BioPharma worth $58.8M as of Q2 2026.
  • State Street bought 271,571 ArriVent BioPharma shares in Q2 2026, an estimated $8.02M.
  • ArriVent BioPharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1752 holding.
  • State Street first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.